Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01712061 · ClinicalTrials.gov registry record · Phase 2

A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy

A Phase 2 study of Diabetic Nephropathy, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
226
Enrollment target
20
Study locations

NCT01712061 is a Phase 2 study of Diabetic Nephropathy that has completed, run by Pfizer. The registered enrollment target is 226 participants, below the 11,406-participant average among 9 other Diabetic Nephropathy trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01712061, a Phase 2 study of Diabetic Nephropathy, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
226 participants
Enrollment target
20
Study locations

Study Summary

The study hypothesis under test is that administration of a CCR2/5 antagonist to subjects with type 2 diabetes and overt nephropathy will result in a reduction in urinary albumin, a surrogate for improved glomerular filtration.

Conditions Studied

Diabetic Nephropathy

Interventions

  • DRUG Placebo
  • DRUG PF-04634817

Study Locations (20)

California

  • North America Research Institute - Azusa
  • California Institute of Renal Research - Chula Vista
  • California Kidney Specialists - Covina
  • Diabetes/Lipid Management and Research Center - Huntington Beach
  • Tower Nephrology Medical Group - Los Angeles
  • Richard S. Cherlin, MD - Los Gatos
  • Providence Clinical Research - North Hollywood
  • Desert Oasis Healthcare Medical Group - Palm Springs
  • Central Coast Nephrology - Salinas
  • California Kidney Specialists - San Dimas

Florida

  • Gulf Coast Endocrine and Diabetes Center - Clearwater
  • Continental Research Corp. - Doral
  • Premier Research Associate, Inc. - Hialeah
  • Prestige Clinical Research Center - Miami
  • Elite Clinical Research - Miami
  • Nephrology Associates of South Miami - Miami
  • Tellus Clinical Research, Inc. - Miami
  • Ocean Blue Medical Research Center, Inc - Miami Springs

Arkansas

  • Medical Investigations, Inc. - Little Rock

Colorado

  • University of Colorado Denver/University of Colorado Hospital - Aurora

Trial Details

FieldValue
Enrollment Target 226 participants
Start Date 2012-12
Est. Completion 2014-09
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01712061

The ClinicalTrials.gov registry entry for NCT01712061 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 11,406-participant average among 9 other Diabetic Nephropathy trials with a reported enrollment target (98% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetic Nephropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01712061 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Arkansas.

Frequently Asked Questions

What is clinical trial NCT01712061 about?

NCT01712061 is a clinical study titled "A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy". The study hypothesis under test is that administration of a CCR2/5 antagonist to subjects with type 2 diabetes and overt nephropathy will result in a reduction in urinary albumin, a surrogate for improved glomerular filtration.

What is the current status of trial NCT01712061?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 226 participants. The study started on 2012-12. Estimated completion is 2014-09.

What conditions does trial NCT01712061 study?

This clinical trial studies the following conditions: Diabetic Nephropathy.

What interventions are being tested in trial NCT01712061?

The interventions under investigation include: Placebo (DRUG), PF-04634817 (DRUG).

Who is sponsoring clinical trial NCT01712061?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01712061 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetic Nephropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetic Nephropathy

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.